<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00656968</url>
  </required_header>
  <id_info>
    <org_study_id>KMU-IRB00003151</org_study_id>
    <secondary_id>VGHKS95-CT3-11</secondary_id>
    <nct_id>NCT00656968</nct_id>
  </id_info>
  <brief_title>Comparison of Sequential or Concomitant Therapy for Helicobacter Pylori Infection</brief_title>
  <acronym>960025</acronym>
  <official_title>Sequential Versus Concomitant Therapy for Helicobacter Pylori Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kaohsiung Veterans General Hospital.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Kaohsiung Veterans General Hospital.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Helicobacter pylori is a bacteria that infects the lining of the stomach and is associated
      with ulcers. Helicobacter pylori may also increase the long-term risk of developing certain
      forms of gastric cancer. Curing this infection generally requires that patients take 2 or
      more antibiotic medications and a stomach acid suppressing medication for about two weeks.
      Current treatments do not always cure the infection and a new treatment is being tested in
      this study. The drugs involved in the new 4 drug treatment have been widely used for
      treatment of this infection. It remains unknown what is the best and most cost effective way
      to give them. This study will compare three different ways of using these drugs.

      Subjects must have active Helicobacter pylori infection in order to participate in this
      study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to compare different methods of giving combination drug therapy
      for treating Helicobacter pylori infection of the stomach. The entire study will last less
      than 2 years. Each subject will be participating in the study for approximately 60 days.

      A total of 360 subjects will be asked to participate in this study.

      Before participating in this study, subject's must have undergone to confirm the presence and
      to assess the susceptibility of Helicobacter pylori. Qualified subjects will receive 4 drugs
      which are to be taken as part of the study treatment: an acid suppressing drug (name),
      amoxicillin, clarithromycin and metronidazole. The doses are 1 grams of amoxicillin, 40 mg of
      esomeprazole (Nexium), 500 mg of metronidazole and 250 mg of clarithromycin. Each drug will
      be given twice a day to be taken twice a day with the morning and evening meals. Subjects
      will receive one of three different combinations. The choice of which will be randomly chosen
      by the use of a computer program. The regimes are: all 4 drugs daily for 5 days, all 4 drugs
      daily for 10 days, and two drugs (esomeprazole and amoxicillin) for 5 days then all for drugs
      for 5 additional days.

      Subjects will be asked to return within 4 days after completion of the treatment to evaluate
      how they did with the drugs. They will be asked bring back all unused medication and the
      bottles or containers that the medicine was packaged in. Your medication use and tolerance to
      the study drugs will be assessed. The treatment portion of the study will be complete at this
      point.

      Evaluation of the effect of the treatment will take place 4-6 weeks after the end of therapy.
      Subjects will come back to the study site and will have a UBT or repeat endoscopy, if
      clinically indicated to verify that the Helicobacter pylori has been cured. Subjects will be
      asked not to take antibiotics or any other drugs that may affect the outcome of the breath
      test used to confirm that the treatment was successful.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants in Which H. Pylori Was Eradicated</measure>
    <time_frame>one month after finishing study drugs</time_frame>
    <description>Evaluate eradication outcome by endoscopy urease test and histology or urea breath test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Had Good Drug Compliance</measure>
    <time_frame>one month after finishing test therapy</time_frame>
    <description>Good drug compliance is defined as taking equal to or more than 80% of eradication medicines</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">232</enrollment>
  <condition>Helicobacter Infection</condition>
  <arm_group>
    <arm_group_label>10-day concomitant therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>esomeprazole and amoxicillin and clarithromycin and metronidazole for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10-day sequential therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>esomeprazole and amoxicillin for 5 days, followed by esoprazole and clarithromycin and metronidazole for 5 more days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>10-day sequential treatment</intervention_name>
    <description>esomeprazole (40 mg daily) from day 1 to day 10, amoxicillin (1 g, bid) from day 1 to day 5, clarithromycin (500 mg, bid) from day 6 to day 10, metronidazole (500 mg, bid) from day 6 to day 10</description>
    <arm_group_label>10-day sequential therapy</arm_group_label>
    <other_name>Nexium-based sequential therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>10-day concomitant therapy</intervention_name>
    <description>esomeprazole (40 mg, bid) from day 1 to day 10, amoxicillin (1 g, bid) from day 1 to day 10, clarithromycin (500 mg, bid) from day 1 to day 10, metronidazole (500 mg, bid) from day 1 to day 10</description>
    <arm_group_label>10-day concomitant therapy</arm_group_label>
    <other_name>Nexium-based quadruple therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or non-pregnant female aged 18 to 75 years inclusively.

          -  Mental and legal ability to give a written informed consent.

          -  Active H. pylori infection.

        Exclusion Criteria:

          -  Previous surgery of the stomach such as partial gastrectomy.

          -  Use of antibiotics within the preceding 30 days.

          -  Regular use of bismuth compounds (&gt;3 times per week) in the 30 days before enrollment.

          -  Presence of serious medical condition(s) precluding participation or endoscopy with
             biopsy.

          -  Use of concomitant medication(s) known to interact with study medication.

          -  Presence of Zollinger-Ellison Syndrome.

          -  Pregnancy or lactation.

          -  Allergy to any of the study medications.

          -  Contraindication(s) to the use of any of the study drugs.

          -  Participation in a clinical trial within the last 30 days.

          -  Unwillingness to abstain from alcoholic beverages.

          -  Patients taking other medications including warfarin, antipsychotics, or chronic
             NSAIDs will also be excluded. Aspirin at a dose not more than 325 mg/day will be
             permitted.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ching-Kuan Liu, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Kaohsiung Medical Univestity</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Y Graham, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Baylor College of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antone R Opekun, PA-C</last_name>
    <role>Study Director</role>
    <affiliation>Baylor College of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Deng-Chyang Wu, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kaohsiung Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chung-Ho Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>807</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Veterans General Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>813</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <link>
    <url>http://www.bcm.edu/medicine/gi/</url>
    <description>Graham, D.Y. / Opekun, A.R.</description>
  </link>
  <reference>
    <citation>Francavilla R, Lionetti E, Castellaneta SP, Magistà AM, Boscarelli G, Piscitelli D, Amoruso A, Di Leo A, Miniello VL, Francavilla A, Cavallo L, Ierardi E. Improved efficacy of 10-Day sequential treatment for Helicobacter pylori eradication in children: a randomized trial. Gastroenterology. 2005 Nov;129(5):1414-9.</citation>
    <PMID>16285942</PMID>
  </reference>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 3, 2008</study_first_submitted>
  <study_first_submitted_qc>April 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2008</study_first_posted>
  <results_first_submitted>August 17, 2010</results_first_submitted>
  <results_first_submitted_qc>July 5, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 2, 2011</results_first_posted>
  <last_update_submitted>September 14, 2015</last_update_submitted>
  <last_update_submitted_qc>September 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kaohsiung Veterans General Hospital.</investigator_affiliation>
    <investigator_full_name>Ping-I (William) Hsu, M.D.</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>peptic ulcer disease</keyword>
  <keyword>gastric cancer</keyword>
  <keyword>therapeutics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Helicobacter Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Esomeprazole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>We surveyed patients who visited the gastroenterological clinic of Kaohsiung Medical University Hospital (KMUH), Kaohsiung Veteran General Hospital (KVGH). A total of 232 H. pylori-infected patients were randomly assigned to sequential (n = 117) or concomitant (n = 115) therapies.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Concomitant Therapy (A)</title>
          <description>esoprazole (40 mg, bid), amoxicillin (1 g, bid), clarithromycin (500 mg, bid) and metronidazole (500 mg, bid) for 10 days</description>
        </group>
        <group group_id="P2">
          <title>Sequential Therapy (B)</title>
          <description>esoprazole (40 mg, bid) from day 1 to day 10, amoxicillin (1 g, bid) from day 1 to day 5, clarithromycin (500 mg, bid) from day 6 to day 10, and metronidazole (500 mg, bid) from day 6 to day 10</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="115"/>
                <participants group_id="P2" count="117"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="115"/>
                <participants group_id="P2" count="117"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Concomitant Therapy (A)</title>
          <description>esoprazole (40 mg, bid), amoxicillin (1 g, bid), clarithromycin (500 mg, bid) and metronidazole (500 mg, bid) for 10 days</description>
        </group>
        <group group_id="B2">
          <title>Sequential Therapy (B)</title>
          <description>esoprazole (40 mg, bid) from day 1 to day 10, amoxicillin (1 g, bid) from day 1 to day 5, clarithromycin (500 mg, bid) from day 6 to day 10, and metronidazole (500 mg, bid) from day 6 to day 10</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="115"/>
            <count group_id="B2" value="117"/>
            <count group_id="B3" value="232"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="98"/>
                    <measurement group_id="B2" value="99"/>
                    <measurement group_id="B3" value="197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.8" spread="11.3"/>
                    <measurement group_id="B2" value="51.7" spread="12"/>
                    <measurement group_id="B3" value="51.74" spread="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Taiwan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="115"/>
                    <measurement group_id="B2" value="117"/>
                    <measurement group_id="B3" value="232"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants in Which H. Pylori Was Eradicated</title>
        <description>Evaluate eradication outcome by endoscopy urease test and histology or urea breath test</description>
        <time_frame>one month after finishing study drugs</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Concomitant Therapy (A)</title>
            <description>esoprazole (40 mg, bid), amoxicillin (1 g, bid), clarithromycin (500 mg, bid) and metronidazole (500 mg, bid) for 10 days</description>
          </group>
          <group group_id="O2">
            <title>Sequential Therapy (B)</title>
            <description>esoprazole (40 mg, bid) from day 1 to day 10, amoxicillin (1 g, bid) from day 1 to day 5, clarithromycin (500 mg, bid) from day 6 to day 10, and metronidazole (500 mg, bid) from day 6 to day 10</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants in Which H. Pylori Was Eradicated</title>
          <description>Evaluate eradication outcome by endoscopy urease test and histology or urea breath test</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                    <measurement group_id="O2" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Had Good Drug Compliance</title>
        <description>Good drug compliance is defined as taking equal to or more than 80% of eradication medicines</description>
        <time_frame>one month after finishing test therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Concomitant Therapy (A)</title>
            <description>esoprazole (40 mg, bid), amoxicillin (1 g, bid), clarithromycin (500 mg, bid) and metronidazole (500 mg, bid) for 10 days</description>
          </group>
          <group group_id="O2">
            <title>Sequential Therapy (B)</title>
            <description>esoprazole (40 mg, bid) from day 1 to day 10, amoxicillin (1 g, bid) from day 1 to day 5, clarithromycin (500 mg, bid) from day 6 to day 10, and metronidazole (500 mg, bid) from day 6 to day 10</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Had Good Drug Compliance</title>
          <description>Good drug compliance is defined as taking equal to or more than 80% of eradication medicines</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="117"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106"/>
                    <measurement group_id="O2" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Concomitant Therapy (A)</title>
          <description>esoprazole (40 mg, bid), amoxicillin (1 g, bid), clarithromycin (500 mg, bid) and metronidazole (500 mg, bid) for 10 days</description>
        </group>
        <group group_id="E2">
          <title>Sequential Therapy (B)</title>
          <description>esoprazole (40 mg, bid) from day 1 to day 10, amoxicillin (1 g, bid) from day 1 to day 5, clarithromycin (500 mg, bid) from day 6 to day 10, and metronidazole (500 mg, bid) from day 6 to day 10</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>bad taste</sub_title>
                <description>Patients had taste perversion.</description>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="115"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <description>Patients had dizziness discomforts.</description>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="115"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="115"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="117"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="115"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="117"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The trial was performed in a single country</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Ping-I Hsu</name_or_title>
      <organization>Kaohsiung Veterans General Hospital</organization>
      <phone>886-7-3422121 ext 8233</phone>
      <email>pihsu@isca.vghks.gov.tw</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

